Switch from agalsidase beta to agalsidase alfa in the enzyme replacement therapy of patients with fabry disease in Latin America
Medicina (B.Aires); 77 (3), 2017
There are currently two available enzyme replacement therapies for Fabry disease and little information regarding efficacy and safety of switching therapies. Between 2009 and 2012 there was a worldwide shortage of agalsidase beta and patients on that enzyme were switched to agalsidase alfa. This retrospe...
Sustitución de Medicamentos, Terapia de Reemplazo Enzimático, Enfermedad de Fabry/tratamiento farmacológico, Tasa de Filtración Glomerular/efectos de los fármacos, Isoenzimas/uso terapéutico, Riñón/efectos de los fármacos, América Latina, Proteínas Recombinantes, Estudios Retrospectivos, alfa-Galactosidasa/administración & dosificación, alfa-Galactosidasa/farmacología, alfa-Galactosidasa/uso terapéutico